The future of heart disease treatment may change after a study found that a common post-heart attack medication may not be as ...

When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what ...

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) ...

Rare genetic variants known to cause cardiomyopathy, an inherited cause of a weak heart, can increase the risk of patients ...

If you’re looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) receptor ...

Research shows semaglutide — commonly sold as Ozempic or Wegovy — can improve kidney function and survival rates for people ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.

GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and ...

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Leading medical ...

Dihydropyridine calcium-channel-blockers (DCCBs), used to treat high blood pressure, could speed up the progression of kidney ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...

New science found menopause changes the heart at a genetic level and HRT may offer more protection than previously thought.